CAR-T Cell Therapy: Just the First Step for Immuno-Oncology

(DGIwire) – The U.S. Food and Drug Administration’s recent approval of Novartis’ gene therapy—for the treatment of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia—represents a watershed moment for healthcare. As Healio recently reported, Kymriah provides unprecedented benefits to poor prognosis patients who have exhausted all other treatment options. What makes […]

close